| Bioactivity | Selegiline (Deprenyl) is a potent, selective and irreversible inhibitor of MAO-B, with an IC50 of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC50=23 μM). Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder[1][2][3]. |
| Invitro | Selegiline (1 nM-1 μM) inhibits recombinant human MAO-B in a concentration-dependent manner[1].Selegiline (10 mM) increases the efflux of norepinephrine (NE), dopamine (DA) and serotonin (5-HT) from the rat hypothalamus in vitro. Selegiline inhibits the efflux of dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) in a dose-dependent manner[3]. |
| In Vivo | Selegiline (1 mg/kg; i.p. daily for 24 days) reduces Cocaine self-administration of mice and does not affect Cocaine-caused body weight loss. Selegiline reduces 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) concentrations in frontal cortex[4]. Animal Model: |
| Name | Selegiline |
| CAS | 14611-51-9 |
| Formula | C13H17N |
| Molar Mass | 187.28 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chaurasiya ND, et, al. Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana). Molecules. 2019 Feb 23;24(4):810. [2]. Tatton WG, et, al. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996 Dec;47(6 Suppl 3):S171-83. [3]. MohanKumar PS, et, al. Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitro. Brain Res Bull. 2001 Apr;54(6):675-80. [4]. Ho MC, et, al. Chronic treatment with monoamine oxidase-B inhibitors decreases cocaine reward in mice. Psychopharmacology (Berl). 2009 Jul;205(1):141-9. |